title: A bedtime dose of ARB was better than a morning dose in improving baroreflex sensitivity and urinary albumin excretion--the J-TOP study.
abstract: The hypothesis that the bedtime dosing of angiotensin receptor blocker (ARB) is superior to morning dose in improving baroreflex sensitivity (BRS) and urinary albumin/creatinine ratio (UACR) was tested in this study. Baroreflex sensitivity was measured at baseline and at 6th month (N = 109) and was found to increase in the bedtime-dose group (P = .004), but not in the morning-dose group. The correlations between the change in BRS and the change in UACR were insignificant in the morning-dose group (r = 0.17, P = .26), but were significant in the bedtime-dose group (r = -0.29, P = .04). In conclusion, the improvement of BRS could be one of the mechanisms by which bedtime dosing of ARB confers renal protection.
authors.affiliation: Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan. ke112@jichi.ac.jp
authors.forename: Kazuo
authors.initials: K
authors.lastname: Eguchi
authors.forename: Motohiro
authors.initials: M
authors.lastname: Shimizu
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hoshide
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Shimada
authors.forename: Kazuomi
authors.initials: K
authors.lastname: Kario
mesh_terms: D000368:Aged; D000419:Albuminuria / Q000652:urine; D057911:Angiotensin Receptor Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D017704:Baroreflex / Q000187:drug effects*; D001794:Blood Pressure / Q000502:physiology; D003404:Creatinine / Q000097:blood / Q000652:urine; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D057911:Angiotensin Receptor Antagonists; D003404:Creatinine